Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injective anti-diabetic
drugs that improve glycemic control and many other atherosclerosis-related parameters in …

Glucagon-like peptide-1 receptor analogues/agonists (GLP-1RAs) are well established as
effective adjuncts to lifestyle modification in the treatment of type 2 diabetes (T2D) as …

OBJECTIVE Compare the efficacy and safety of monotherapy with dulaglutide, a once-
weekly GLP-1 receptor agonist, to metformin-treated patients with type 2 diabetes. The …

Diabetes and glucose intolerance are common complications of chronic pancreatitis, yet
clinical guidance on their detection, classification, and management is lacking. Methods A …

Background: Once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) are new
drugs for the treatment of type 2 diabetes. Purpose: To summarize evidence for the …

Accumulating evidence implicates glucagon-like peptide-1 (GLP-1) to have, beyond glucose
maintenance, a beneficial role in the gastrointestinal tract. Here, we review emerging data …

Background: A few Randomized Controlled Trials (RCTs) have evaluated the use of
liraglutide in Type 1 Diabetes (T1D). Through the present systematic review and meta …

The gastrointestinal hormone glucagon‐like peptide‐1 (GLP‐1) lowers postprandial glucose
concentrations by regulating pancreatic islet‐cell function, with stimulation of glucose …

In this open‐label multicentre randomised controlled trial, we investigated three peri‐
operative treatment strategies to lower glucose and reduce the need for rescue insulin in …

Objective The purpose of this study is to evaluate the optimal dose of tirzepatide (TZP) for
the treatment of type 2 diabetes mellitus (T2DM) by meta-analysis and trial sequential …